Literature DB >> 3802384

A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix.

R E Coleman, P G Harper, C Gallagher, R Osborne, E M Rankin, A C Silverstone, M L Slevin, R L Souhami, J S Tobias, C W Trask.   

Abstract

Forty-one patients with advanced progressing carcinoma of the cervix were treated with ifosfamide 1.5 g/m2 daily in a 30-min infusion for 5 days every 3 weeks. The overall response rate (complete + partial) was 12/39 (31%), or 12/30 (40%) in those who had not received previous chemotherapy. Six patients achieved a complete remission of disease and four of these remain disease-free 24-39 months later. Durable response were seen in patients with disease progressing after radical radiotherapy. Bone marrow suppression was the dose-limiting toxicity and led to dosage modification in 24 patients. Nausea and vomiting was experienced by all patients at some time during therapy and all patients developed alopecia. Mild neurological toxicity occurred in seven patients but severe life-threatening neurotoxicity was not seen with this schedule of administration. Further studies are needed to identify the optimum dose and schedule of ifosfamide and to ascertain its place in combination therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3802384     DOI: 10.1007/bf00273403

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

1.  Encephalopathy associated with ifosphamide/mesna therapy.

Authors:  C A Meanwell; A E Blake; T N Latief; G Blackledge; J J Mould; D R Blake; I C Shaw; L Honigsberger; D Spooner; A C Williams
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

2.  Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.

Authors:  J J Costanzi; L R Morgan; J Hokanson
Journal:  Semin Oncol       Date:  1982-12       Impact factor: 4.929

3.  Ifosfamide--current aspects and perspectives.

Authors:  P Hilgard; K Herdrich; W Brade
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

4.  High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma.

Authors:  R Stuart-Harris; P G Harper; S B Kaye; E Wiltshaw
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

5.  Carcinoma of the cervix at the Royal Marsden Hospital, London, 1962--70: survival results.

Authors:  R F Mould; J F Staffurth
Journal:  Br J Radiol       Date:  1979-02       Impact factor: 3.039

6.  Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma.

Authors:  M E Heim; R Fiene; E Schick; E Wolpert; W Queisser
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

7.  Long term results of treatment of carcinoma of cervix.

Authors:  B Jolles
Journal:  Br J Obstet Gynaecol       Date:  1980-04

8.  Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

Authors:  T Thigpen; H Shingleton; H Homesley; L Lagasse; J Blessing
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

9.  Cervical carcinoma: a drug-responsive tumor--experience with combined cisplatin, vinblastine, and bleomycin therapy.

Authors:  M Friedlander; S B Kaye; A Sullivan; K Atkinson; P Elliott; M Coppleson; R Houghton; J Solomon; D Green; P Russell
Journal:  Gynecol Oncol       Date:  1983-10       Impact factor: 5.482

10.  Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.

Authors:  B M Bryant; M Jarman; H T Ford; I E Smith
Journal:  Lancet       Date:  1980-09-27       Impact factor: 79.321

View more
  10 in total

Review 1.  Chemotherapy for advanced or recurrent carcinoma of the cervix.

Authors:  J D Bloss
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

Review 2.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

3.  Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer.

Authors:  H Kühnle; H G Meerpohl; W Eiermann; S Röben; L Lenaz; W Achterrath
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.

Authors:  G P Sutton; J A Blessing; G Photopulos; M L Berman; H D Homesley
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix.

Authors:  R E Coleman; J M Clarke; M L Slevin; J Sweetenham; C J Williams; P Blake; F Calman; E Wiltshaw; P G Harper
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Phase II studies of ifosfamide alone and in combination in cancer of the cervix.

Authors:  G Blackledge; E J Buxton; J J Mould; J Monaghan; M Paterson; J Tobias; C Alcock; D Spooner; C A Meanwell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

8.  Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.

Authors:  Hiroko Machida; Aida Moeini; Marcia A Ciccone; Sayedamin Mostofizadeh; Tsuyoshi Takiuchi; Laurie L Brunette; Lynda D Roman; Koji Matsuo
Journal:  Am J Clin Oncol       Date:  2018-09       Impact factor: 2.339

Review 9.  Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers.

Authors:  Jonathan D Black; Salvatore Lopez; Emiliano Cocco; Carlton L Schwab; Diana P English; Alessandro D Santin
Journal:  Toxins (Basel)       Date:  2015-04-01       Impact factor: 4.546

Review 10.  Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.

Authors:  Sung Jong Lee; Andrew Yang; T C Wu; Chien Fu Hung
Journal:  J Gynecol Oncol       Date:  2016-05-31       Impact factor: 4.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.